Literature DB >> 18443110

A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.

Guillermo Garcia-Effron1, Santosh K Katiyar, Steven Park, Thomas D Edlind, David S Perlin.   

Abstract

Candida parapsilosis has emerged as a common cause of invasive fungal infection, especially in Latin America and in the neonatal setting. C. parapsilosis is part of a closely related group of organisms that includes the species Candida orthopsilosis and Candida metapsilosis. All three species show elevated MICs for the new echinocandin class drugs caspofungin, micafungin, and anidulafungin relative to other Candida species. Despite potential impacts on therapy, the mechanism behind this reduced echinocandin susceptibility has not been determined. In this report, we investigated the role of a naturally occurring Pro-to-Ala substitution at amino acid position 660 (P660A), immediately distal to the highly conserved hot spot 1 region of Fks1p, in the reduced-echinocandin-susceptibility phenotype. Kinetic inhibition studies demonstrated that glucan synthase from the C. parapsilosis group was 1 to 2 logs less sensitive to echinocandin drugs than the reference enzyme from C. albicans. Furthermore, clinical isolates of C. albicans and C. glabrata which harbor mutations at this equivalent position also showed comparable 2-log decreases in target enzyme sensitivity, which correlated with increased MICs. These mutations also resulted in 2.4- to 18.8-fold-reduced V(max) values relative to those for the wild-type enzyme, consistent with kinetic parameters obtained for C. parapsilosis group enzymes. Finally, the importance of the P660A substitution for intrinsic resistance was confirmed by engineering an equivalent P647A mutation into Fks1p of Saccharomyces cerevisiae. The mutant glucan synthase displayed characteristic 2-log decreases in sensitivity to the echinocandin drugs. Overall, these data firmly indicate that a naturally occurring P660A substitution in Fks1p from the C. parapsilosis group accounts for the reduced susceptibility phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18443110      PMCID: PMC2443908          DOI: 10.1128/AAC.00262-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

Review 1.  The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.

Authors:  Nathan P Wiederhold; Russell E Lewis
Journal:  Expert Opin Investig Drugs       Date:  2003-08       Impact factor: 6.206

Review 2.  Echinocandin antifungal drugs.

Authors:  David W Denning
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

3.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

4.  Risk factors for Candida species colonization of neonatal intensive care unit patients.

Authors:  L Saiman; E Ludington; J D Dawson; J E Patterson; S Rangel-Frausto; R T Wiblin; H M Blumberg; M Pfaller; M Rinaldi; J E Edwards; R P Wenzel; W Jarvis
Journal:  Pediatr Infect Dis J       Date:  2001-12       Impact factor: 2.129

5.  Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation.

Authors:  W Lamar Smith; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades.

Authors:  Amar Safdar; David S Perlin; Donald Armstrong
Journal:  Diagn Microbiol Infect Dis       Date:  2002-09       Impact factor: 2.803

7.  The predictors of outcome in immunocompetent patients with hematogenous candidiasis.

Authors:  Amar Safdar; Thomas W Bannister; Zeenat Safdar
Journal:  Int J Infect Dis       Date:  2004-05       Impact factor: 3.623

Review 8.  In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

Authors:  Ana Espinel-Ingroff
Journal:  Rev Iberoam Micol       Date:  2003-12       Impact factor: 1.044

9.  Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase.

Authors:  P Mazur; N Morin; W Baginsky; M el-Sherbeini; J A Clemas; J B Nielsen; F Foor
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

10.  The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase.

Authors:  C M Douglas; F Foor; J A Marrinan; N Morin; J B Nielsen; A M Dahl; P Mazur; W Baginsky; W Li; M el-Sherbeini
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

View more
  117 in total

Review 1.  Minority report: the intestinal mycobiota in systemic infections.

Authors:  Thierry Rolling; Tobias M Hohl; Bing Zhai
Journal:  Curr Opin Microbiol       Date:  2020-06-27       Impact factor: 7.934

Review 2.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

3.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

Review 4.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

5.  Echinocandin failure case due to a previously unreported FKS1 mutation in Candida krusei.

Authors:  Rasmus Hare Jensen; Ulrik Stenz Justesen; Annika Rewes; David S Perlin; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

6.  Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.

Authors:  Jeffrey M Rybak; C Michael Dickens; Josie E Parker; Kelly E Caudle; Kayihura Manigaba; Sarah G Whaley; Andrew T Nishimoto; Arturo Luna-Tapia; Sujoy Roy; Qing Zhang; Katherine S Barker; Glen E Palmer; Thomas R Sutter; Ramin Homayouni; Nathan P Wiederhold; Steven L Kelly; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 7.  The Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases.

Authors:  Ilan S Schwartz; Thomas F Patterson
Journal:  Curr Infect Dis Rep       Date:  2018-02-05       Impact factor: 3.725

8.  Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

Authors:  M A Pfaller; D J Diekema; L Ostrosky-Zeichner; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; M A Ghannoum; C C Knapp; D J Sheehan; T J Walsh
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

Review 9.  Caspofungin: in pediatric patients with fungal infections.

Authors:  Karly P Garnock-Jones; Susan J Keam
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

10.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.